Linker technology in antibody-drug conjugates for cancer treatment

Research output: Contribution to journalArticlepeer-review


Linker technology is important for antibody-drug conjugate development. Linker connects antibody and anti-cancer agent. The linkage between antibody-drug conjugate must be stable during blood circulation, yet the anti-cancer agent should be released at cancer lesion. In this manuscript, the aspect of various linkers and spacers will be described.

Original languageEnglish
Pages (from-to)406-411
Number of pages6
JournalDrug Delivery System
Issue number5
Publication statusPublished - 2013


  • Antibody-drug conjugate
  • Diketopiperazine
  • Linker
  • Spacer
  • Specifier


Dive into the research topics of 'Linker technology in antibody-drug conjugates for cancer treatment'. Together they form a unique fingerprint.

Cite this